Treatment library
Loading treatment roster
Preparing current medications, procedures, devices, and historical context.
Treatment library
Preparing current medications, procedures, devices, and historical context.
Sibutramine’s obesity-drug story ended after cardiovascular safety concerns led the FDA to recommend against continued use and the product left the U.S. market.
Removed from the U.S. market after cardiovascular outcome concerns changed the benefit-risk profile.
Central norepinephrine and serotonin reuptake inhibition
Not applicable as a current treatment option.
Central norepinephrine and serotonin reuptake inhibition
Sibutramine’s obesity-drug story ended after cardiovascular safety concerns led the FDA to recommend against continued use and the product left the U.S. market.
legacy
discontinued
1997
2010
Meridia
sibutramine
Abbott (historical)
No current U.S. product.
sibutramine
Discontinued product; not a current market option.
Not applicable as a current treatment option.
Historical reference only.
Meridia remains relevant because it shaped how regulators and clinicians think about long-term cardiovascular risk in obesity pharmacotherapy.
Its significance today is as a cardiovascular-safety cautionary example in obesity-drug history.
elevated blood pressure, elevated heart rate, dry mouth, insomnia, cardiovascular event risk
Central norepinephrine and serotonin reuptake inhibition
Historical once-daily oral dosing.
Historical oral capsule.
Discontinued obesity medication
Historical oral capsule.
Its significance today is as a cardiovascular-safety cautionary example in obesity-drug history.
These are the official or reference sources used to anchor this treatment profile.
Treatment availability, dosing, cash pricing, and insurance coverage change often. Verify current details with your clinician, pharmacist, surgeon, device program, and insurer before starting, switching, or paying for treatment.